Genocea Biosciences (GNCA) and Its Peers Financial Review
Genocea Biosciences (NASDAQ: GNCA) is one of 185 public companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its peers? We will compare Genocea Biosciences to related companies based on the strength of its institutional ownership, risk, earnings, valuation, profitability, dividends and analyst recommendations.
This is a summary of current recommendations and price targets for Genocea Biosciences and its peers, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Genocea Biosciences Competitors||558||2509||6741||133||2.65|
Earnings & Valuation
This table compares Genocea Biosciences and its peers top-line revenue, earnings per share and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Genocea Biosciences||$230,000.00||-$49.57 million||-0.56|
|Genocea Biosciences Competitors||$217.40 million||-$39.57 million||-54.04|
Genocea Biosciences’ peers have higher revenue and earnings than Genocea Biosciences. Genocea Biosciences is trading at a higher price-to-earnings ratio than its peers, indicating that it is currently more expensive than other companies in its industry.
Institutional and Insider Ownership
34.7% of Genocea Biosciences shares are held by institutional investors. Comparatively, 48.1% of shares of all “Biotechnology & Medical Research” companies are held by institutional investors. 6.7% of Genocea Biosciences shares are held by company insiders. Comparatively, 14.5% of shares of all “Biotechnology & Medical Research” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.
This table compares Genocea Biosciences and its peers’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Genocea Biosciences Competitors||-4,355.47%||-475.72%||-42.86%|
Volatility and Risk
Genocea Biosciences has a beta of 1.94, meaning that its stock price is 94% more volatile than the S&P 500. Comparatively, Genocea Biosciences’ peers have a beta of 1.49, meaning that their average stock price is 49% more volatile than the S&P 500.
Genocea Biosciences peers beat Genocea Biosciences on 8 of the 13 factors compared.
Genocea Biosciences Company Profile
Genocea Biosciences, Inc., is harnessing the power of T cell immunity to develop vaccines and immunotherapies company. The Company uses its discovery platform, AnTigen Lead Acquisition System (ATLAS), to design vaccines and immunotherapies that act, in part, through T cell (or cellular) immune responses. The Company has one product candidate in Phase III clinical development, GEN-003, an immunotherapy for the treatment of genital herpes. It also has a pre-clinical immuno-oncology program focused on personalized cancer vaccines (GEN-009). The GEN-009 program leverages ATLAS to identify patient neoantigens, or newly formed antigens unique to each patient, that are associated with that individual’s tumor.
Receive News & Stock Ratings for Genocea Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genocea Biosciences and related stocks with our FREE daily email newsletter.